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osting by EAbstract Diabetic retinopathy, the most common long-term complication of diabetes mellitus,
remains one of the leading causes of blindness worldwide. Strict metabolic control, tight blood pres-
sure control, laser photocoagulation, and vitrectomy remain the standard care for diabetic retinop-
athy. Focal/grid photocoagulation is a better treatment than intravitreal triamcinolone acetonide in
eyes with diabetic macular edema and should be considered as the ﬁrst-line therapeutic option. The
current evidence suggests that intravitreal triamcinolone acetonide or anti-vascular endothelial
growth factor agents result in a temporary improvement of visual acuity and a short-term reduction
in central macular thickness in patients with refractory diabetic macular edema and are an effective
adjunctive treatments to laser photocoagulation or vitrectomy. However, triamcinolone is associ-
ated with risks of elevated intraocular pressure and cataract. Vitrectomy with the removal of the
posterior hyaloid without internal limiting membrane peeling seems to be effective in eyes with per-
sistent diffuse diabetic macular edema, particularly in eyes with associated vitreomacular traction.
Emerging therapies include islet cell transplantation, fenoﬁbrate, ruboxistaurin, pharmacologic vit-
reolysis, rennin-angiotensin system blockers, and peroxisome proliferator-activated receptor
gamma agonists.
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Diabetic retinopathy is the most common microvascular com-
plication of diabetes and remains one of the leading causes of
blindness worldwide among adults aged 20–74 years. The two
most important visual complications of diabetic retinopathy
are diabetic macular edema (DME) and proliferative diabetic
retinopathy (PDR). The prevalence of diabetic retinopathy in-
creases with duration of diabetes, and nearly all persons with
type 1 diabetes and more than 60% of those with type 2 have
some retinopathy after 20 years. In the Wisconsin Epidemiol-
ogic Study of Diabetic Retinopathy (WESDR), 3.6% of youn-
ger-onset patients (type 1 diabetes) and 1.6% of older-onset
patients (type 2 diabetes) were legally blind (Fong et al., 2003).
2. Evidence-based patient care
Five large randomized controlled trials provide the scientiﬁc
basis for care in the diabetic patient to preserve vision.
2.1. The diabetes control and complications trial (DCCT)
The DCCT randomized 1441 patients with type 1 diabetes to
receive intensive glycemic or conventional therapy. Over
6.5 years of follow-up, intensive treatment [median HbA1c
(glycosylated hemoglobin A1c), 7.2%] reduced the incidence
of diabetic retinopathy by 76% and progression of diabetic ret-
inopathy by 54%, as compared with the conventional treat-
ment (DCCT, 1993). Long-term observational DCCT data
showed that despite gradual equalization of HbA1c values
after study termination, the rate of diabetic retinopathy
progression in the former intensively treated group remained
signiﬁcantly lower than in the former conventional group(‘‘metabolic memory’’) (White et al., 2008), emphasizing the
importance of instituting tight glycemic control early in the
course of diabetes.
Tight glycemic control has two clinically important adverse
effects. First, there is risk of early worsening of diabetic reti-
nopathy. In the DCCT, this occurred in 13.1% of the intensive
versus 7.6% of the conventional treatment group. However,
this effect was reversed by the 18th month, and no case of early
worsening resulted in serious visual loss. In the DCCT, the
long-term beneﬁts of intensive insulin treatment greatly out-
weighted the risks of early worsening of diabetic retinopathy.
Therefore, ophthalmoscopic monitoring before initiation of
intensive treatment and at 3-month intervals for 6–12 months
thereafter seems to be appropriate when intensive treatment
is initiated in patients with long-standing poor glycemic con-
trol, particularly if retinopathy is at or past the moderate
non-proliferative stage. In patients whose retinopathy is al-
ready approaching the high-risk stage, it may be prudent to de-
lay the initiation of intensive treatment until photocoagulation
can be completed, particularly if the HbA1c level is high
(DCCT, 1998). Second, tight glycemic control was associated
with more frequent severe hypoglycemic episodes compared
to the conventional group (DCCT, 1993).
2.2. The United Kingdom prospective diabetes study (UKPDS)
The UKPDS randomized 3867 patients with newly diagnosed
type 2 diabetes to receive intensive or conventional therapy.
After 12 years of follow-up, the progression of diabetic reti-
nopathy was reduced by 21% and the need for laser photoco-
agulation by 29% in the intensive versus the conventional
treatment group (UKPDS Group 33, 1998). The UKPDS also
investigated the inﬂuence of tight blood pressure control. A
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randomized to less tight (<180/105 mmHg) and tight blood
pressure control (<150/85 mmHg). With a median follow-up
of 8.4 years, patients assigned to the tight control group had
a 34% reduction in progression of retinopathy and a 47% re-
duced risk of deterioration in visual acuity of three lines com-
pared with the less tight control group (UKPDS Group 38,
1998).
2.3. The diabetic retinopathy study (DRS)
The DRS investigated whether scatter (panretinal) photocoag-
ulation, compared with indeﬁnite deferral, could reduce the
risk of vision loss from PDR. After 2 years, photocoagulation
was shown to signiﬁcantly reduce severe visual loss (best-
corrected visual acuity of 5/200 or worse) from PDR. The ben-
eﬁt persisted through the entire duration of follow-up and was
greatest among patients whose eyes had high-risk characteris-
tics (Anonymous, 1978). Recently, the Diabetic Retinopathy
Clinical Research Network compared the effects of single-
sitting versus 4-sitting panretinal photocoagulation on macular
edema in subjects with severe nonproliferative or early prolif-
erative diabetic retinopathy with relatively good visual acuity
and no or mild center-involved macular edema. The results
suggest that clinically meaningful differences are unlikely in
optical coherence tomography thickness or visual acuity fol-
lowing application in 1 sitting compared with 4 sittings (Dia-
betic Retinopathy Clinical Research Network, 2009a,b).
2.4. The early treatment diabetic retinopathy study (ETDRS)
The ETDRS demonstrated that focal/grid laser photocoagula-
tion reduced the risk of moderate vision loss (that is, a dou-
bling of the visual angle) from clinically signiﬁcant macular
edema by 50% or more (ETDRS, 1985). ETDRS analyses also
indicated that for patients with type 2 diabetes, it is especially
important to consider scatter photocoagulation at the time of
the development of severe nonproliferative or early prolifera-
tive retinopathy (Ferris, 1996).
A recent randomized controlled trial compared modiﬁed
ETDRS direct/grid photocoagulation technique and mild mac-
ular grid (MMG) laser technique in which microaneurysms are
not treated directly and small mild burns are placed through-
out the macula for DME. Twelve months after treatment,
the MMG technique was less effective at reducing optical
coherence tomography-measured retinal thickening than the
current modiﬁed ETDRS laser photocoagulation approach.
It was concluded that modiﬁed ETDRS focal photocoagula-
tion should continue to be a standard approach for treating
DME (Writing Committee for the Diabetic Retinopathy Clin-
ical Research Network, 2007). Recently, the Diabetic Retinop-
athy Clinical Research Network concluded that focal/grid
photocoagulation remains the standard management for dia-
betic macular edema (Aiello et al., 2010).
2.5. The diabetic retinopathy vitrectomy study (DRVS)
The DRVS randomized 616 eyes with recent vitreous hemor-
rhage reducing visual acuity to 5/200 or less for at least one
month to undergo early vitrectomy within 6 months or deferral
of vitrectomy for one year. After two years of follow-up, 25%
of the early vitrectomy group had visual acuity of 10/20 orbetter compared with 15% of the deferral group. In patients
with type 1 diabetes, who were on average younger and had
more severe PDR, there was a clear-cut advantage for early
vitrectomy, as reﬂected in the percentage of eyes recovering vi-
sual acuity of 10/20 or better (36% versus 12% in the deferral
group). No such advantage was found in the type 2 diabetes
group (16% in the early group versus 18% in the deferral
group) (DRVS, 1985).
The DRS and the ETDRS showed that laser photocoagula-
tion for diabetic retinopathy is effective at slowing the progres-
sion of retinopathy and reducing visual loss, but the treatment
usually does not restore lost vision. Because these treatments
are aimed at preventing vision loss and retinopathy can be
asymptomatic, it is important to identify and treat patients
early in the disease. To achieve this goal, patients with diabetes
should be routinely evaluated to detect treatable disease.
Guidelines for the frequency of diabetic eye examinations have
been largely based on the severity of retinopathy (Fong et al.,
2003).
3. Emerging therapies
Due to the limitations of the current treatments, new therapeu-
tic approaches are being developed.
3.1. Intravitreal triamcinolone acetonide
Intravitreal triamcinolone acetonide (IVTA) is reported to
generate favorable results in the treatment of diffuse DME.
However, the major limitation of IVTA is the recurrence of
DME which develops after a relatively short duration of action
necessitating repeated applications of IVTA which carry risk
and are inconvenient for patients (Kang et al., 2006). This
early disappearance of the effect of IVTA might be consistent
with the results reported by Beer et al. (2003), who calculated
that measurable concentrations of triamcinolone could be ex-
pected to last no longer than 3 months in nonvitrectomized
eyes.
In a prospective randomized controlled trial, eyes with per-
sistent DME after focal/grid photocoagulation received either
4 mg of IVTA or sham injection (saline injection into the sub-
conjunctival space). After 2 years, 19 of 34 (56%) eyes treated
with repeated IVTA had a visual acuity improvement of ﬁve
letters or more compared with 9 of 35 (26%) placebo treated
eyes. An increase of intraocular pressure ofP5 mmHg was ob-
served in 23 of 34 (68%) treated versus 3 of 30 (10%) untreated
eyes. Glaucoma medication was required in 15 of 34 (44%)
treated versus 1 of 30 (3%) untreated eyes. Cataract surgery
was performed in 15 of 28 (54%) treated versus 0 of 21 (0%)
untreated eyes. Two eyes in the IVTA group required trabecu-
lectomy. There was one case of infectious endophthalmitis in
the treatment group (Gillies et al., 2006).
Recent systematic reviews and meta-analysis of randomized
controlled trials for IVTA for laser-refractory DME concluded
that IVTA is effective in improving visual acuity in patients
with refractory DME in the short-term, but the beneﬁts do
not seem to persist in the long-term. A peak beneﬁt of approx-
imately three lines of visual acuity was achieved 1 month post
injection (Rudnisky et al., 2009; Yilmaz et al., 2009).
The Diabetic Retinopathy Clinical Research Network
(2008) reported 2-year results of a multicenter randomized
clinical trial comparing preservative free IVTA and focal/grid
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cal/grid photocoagulation, 1 mg IVTA, or 4 mg IVTA.
Retreatment was given for persistent or new edema at 4-month
intervals. After 4 months, mean visual acuity was better in the
4-mg IVTA group than in either the laser group or the 1-mg
IVTA group. The mean visual acuity 2 years after starting
the treatment was better in the laser group compared to the
steroid-injected groups. Optical coherence tomography results
generally paralleled the visual acuity results. Cataract surgery
performed before the 2-year visit was most frequent in the 4-
mg IVTA group (51%) versus the 1-mg IVTA group (23%)
and the laser group (13%). Increased intraocular pressure
from the baseline by 10 mmHg or more at any visit was most
frequent in the 4-mg IVTA group (33%) versus the 1-mg IVTA
group (16%) and the laser group (4%). More recently, the Dia-
betic Retinopathy Clinical Research Network (2009) reported
that the 3-year visual outcome results were consistent with the
previously published 2-year results. The cumulative probabil-
ity of cataract surgery by 3 years was 31%, 46%, and 83%
in the laser and 1-mg and 4-mg IVTA groups, respectively.
Intraocular pressure increased by more than 10 mmHg at
any visit in 4%, 18%, and 33% of the eyes, respectively. This
randomized study indicated clearly that focal/grid photocoag-
ulation is a better treatment than IVTA in eyes with DME
involving the center of the macula with visual acuity between
20/40 and 20/320. The fact that the 4-mg IVTA group had a
greater positive treatment response on visual acuity and retinal
thickening after 4 months of treatment, whereas the photoco-
agulation group had a greater positive response later, raises
the possibility that combining focal/grid photocoagulation
with IVTA may produce greater beneﬁt for DME than either
focal/grid photocoagulation or IVTA alone (Diabetic Retinop-
athy Clinical Research Network, 2008).
More recently, the Diabetic Retinopathy Clinical Research
Network reported that IVTA (4 mg) appeared to reduce the
risk of progression of diabetic retinopathy. However, the study
concluded that use of IVTA to reduce the likelihood of pro-
gression of retinopathy is not warranted at this time because
of the increased risk of glaucoma and cataract associated with
IVTA and because PDR already can be treated successfully
and safely with panretinal photocoagulation (Bressler et al.,
2009).
Several small randomized clinical trials demonstrated that
the combination of laser photocoagulation (panretinal and
macular) with IVTA was associated with improved best-
corrected visual acuity and decreased central macular thick-
ness and total macular volume when compared with laser
photocoagulation alone for the treatment of PDR and macular
edema (Lam et al., 2007; Maia et al., 2009). On the other hand,
a recent study demonstrated no beneﬁcial effect of combined
IVTA plus panretinal photocoagulation and macular photoco-
agulation in eyes with coexisting high-risk PDR and clinically
signiﬁcant macular edema as compared with panretinal photo-
coagulation and macular photocoagulation as standard treat-
ment in those patients (Mirshahi et al., 2010).
Recently, two studies compared the morphological and vi-
sual acuity outcomes associated with a single intravitreal injec-
tion of triamcinolone acetonide versus bevacizumab for the
treatment of DME. These studies concluded that one single
intravitreal injection of triamcinolone showed better results
in reducing DME and in the improvement of visual acuity than
that of bevacizumab in the short-term management of DME.The reduction effect of bevacizumab on DME was weaker
and shorter than that by triamcinolone. However, intravitreal
bevacizumab had the advantage of intraocular pressure stabil-
ity compared with the triamcinolone injection (Paccola et al.,
2008; Shimura et al., 2008).
3.2. Anti-vascular endothelial growth factor (VEGF) treatment
Currently, there are four anti-VEGF agents which have been
used in the management of diabetic retinopathy, including
pegaptanib (Macugen; Pﬁzer, Inc., New York, USA),
ranibizumab (Lucentis; Genentech, Inc., South San Francisco,
California, USA), bevacizumab (Avastin; Genentech, Inc.),
and VEGF Trap-Eye (Regeneron Pharmaceuticals, Inc.,
Tarrytown, New York, USA).
3.2.1. Pegaptanib
Pegaptanib is a pegylated RNA aptamer directed against the
VEGF-A 165 isoform. A phase II clinical trial of intravitreal
pegaptanib in patients with DME with 36 weeks of follow-up
demonstrated better visual acuity outcomes, reduced central
retinal thickness, and reduced need for additional photocoag-
ulation therapy (Cunningham et al., 2005). A retrospective
analysis of the same study on patients with retinal neovascular-
ization at the baseline showed regression of neovascularization
after intravitreal pegaptanib administration (Adamis et al.,
2006). Recently, Querques et al. (2009) demonstrated in a ret-
rospective study that repeated intravitreal pegaptanib pro-
duced signiﬁcant improvement in best-corrected visual acuity
and reduction in mean central macular thickness in patients
with diabetic macular edema. In addition, Gonza´lez et al.
(2009) showed that intravitreal pegaptanib produced short-
term marked and rapid regression of diabetic retinal neovascu-
larization. These data suggest that VEGF blockade may be a
safe and efﬁcacious adjuvant treatment to panretinal photoco-
agulation in PDR.
3.2.2. Ranibizumab
Ranibizumab is a recombinant humanized monoclonal anti-
body fragment with speciﬁcity for all isoforms of human
VEGF-A. Pilot studies of intravitreal ranibizumab demon-
strated reduced foveal thickness andmaintained or improved vi-
sual acuity in patients with DME (Chun et al., 2006). Recently,
Nguyen et al. (2009) demonstrated that during a span of
6 months, repeated intravitreal injections of ranibizumab pro-
duced a signiﬁcantly better visual outcome than focal/grid laser
treatment in patients with DME. The Diabetic Retinopathy
Clinical Research Network (2010a) evaluated intravitreal
0.5 mg ranibizumab or 4 mg triamcinolone combined with fo-
cal/grid laser comparedwith focal/grid laser alone for treatment
of diabetic macular edema. The 1-year mean change (±stan-
dard deviation) in the visual acuity letter score from the baseline
was signiﬁcantly greater in the ranibizumab + prompt laser
group and ranibizumab + deferred laser group but not in the
triamcinolone + prompt laser group compared with the
sham + prompt laser group. In the subset of pseudophakic eyes
at the baseline, visual acuity improvement in the triamcino-
lone + prompt laser group appeared comparable to that in
the ranibizumab groups. Two-year visual acuity outcomes were
similar to 1-year outcomes. Elevated intraocular pressure and
cataract surgery were more frequent in the triamcino-
lone + prompt laser group and 0.8% had injection-related
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(2010), in a randomized study, showed that intraocular injection
of ranibizumab provided beneﬁt for diabetic macular edema for
at least 2 years, and when combined with focal or grid laser
treatments, the amount of residual edema was reduced, as were
the frequency of injections needed to control edema.
3.2.3. Vascular endothelial growth factor Trap-Eye
VEGF Trap is a 115 kDa recombinant fusion protein consist-
ing of the VEGF binding domains of human VEGF receptors
1 and 2 fused to the Fc domain of human IgG1. One pilot
study showed that a single intravitreal injection of VEGF
Trap-Eye was well tolerated and was effective in patients with
DME (Do et al., 2009).
3.2.4. Bevacizumab
Bevacizumab is a full length recombinant humanized antibody
active against all isoforms of VEGF-A. It is FDA-approved as
an adjunctive systemic treatment for metastatic colorectal can-
cer. Several studies reported the use of the off-label intravitreal
bevacizumab (IVB) to treat DME, complications of PDR, and
iris neovascularization.
To date, all studies regarding IVB (1.25 mg) for DME ther-
apy, have demonstrated transient beneﬁcial effects with a
requirement for repeated injections (Arevalo et al., 2009a;
Roh et al., 2008; Fang et al., 2008; Lam et al., 2009). Increased
visual acuity with decrease in macular edema with a single injec-
tion of IVB lasts for 4 to 6 weeks with deterioration of visual
acuity and recurrence of macular edema 8 to 12 weeks later
necessitating another injection (Roh et al., 2008; Paccola
et al., 2008). Fang et al. (2008) reported that the improvement
in visual acuity and decrease in macular edema were maintained
for 8 weeks in the non-pretreated eyes, and for 2–4 weeks in the
pretreated eyes. In addition, Yanyali et al. (2007) reported that
IVB inDMEhas no effect on visual acuity andmacular edema in
previously vitrectomized eyes. Similarly, Lam et al. (2009) dem-
onstrated that IVB was more effective in eyes without previous
DME treatment, which included focal or grid laser photocoag-
ulation. Two recent studies demonstrated that IVB at doses of
1.25 and 2.5 mg seems to have similar treatment efﬁcacy in pa-
tients with DME (Lam et al., 2009; Arevalo et al., 2009a).
Bonini-Filho et al. (2009) showed that IVB forDMEwith severe
capillary loss was associated with beneﬁcial effects on vision,
central macular thickness, and total macular volume. Soheilian
et al. (2009) reported that IVB in patients with DME yielded a
better visual outcome 24 weeks later compared with macular
photocoagulation.
Several studies demonstrated that IVB injection resulted in
marked regression of retinal and iris neovascularization, and
rapid resolution of vitreous hemorrhage in patients with
PDR (Arevalo et al., 2009b; Jiang et al., 2008; Wakabayashi
et al., 2008). In addition, IVB injection was demonstrated to
be an effective adjunctive treatment to PRP in the treatment
of high-risk PDR (Tonello et al., 2008; Cho et al., 2009), and
neovascular glaucoma (Wakabayashi et al., 2008). Intravitreal
bevacizumab injection before PRP was found to be beneﬁcial
in preventing PRP-induced visual dysfunction and foveal
thickening and was associated with a greater reduction in the
area of active leaking new vessels than PRP alone in patients
with high-risk PDR (Tonello et al., 2008; Cho et al., 2009).
In addition, Huang et al. (2009) demonstrated that IVB injec-
tion with PRP was effective in inducing rapid regression ofvitreous hemorrhage and may reduce the need for vitrectomy
in eyes with PDR complicated with vitreous hemorrhage.
The use of preoperative IVB injection few days before
planned pars plana vitrectomy for the treatment of complica-
tions of PDR was also found to be efﬁcacious and safe as an
adjuvant treatment to facilitate surgery, prevent rebleeding,
and accelerate postoperative vitreous clear-up (Ahmadieh
et al., 2009; di Lauro et al., 2010). However, tractional retinal
detachment may occur or progress shortly following adminis-
tration of IVB in these patients (Arevalo et al., 2008). Two re-
cent studies demonstrated that IVB injection pretreatment for
diabetic vitrectomy did not inﬂuence rates of postoperative vit-
reous hemorrhage or ﬁnal visual acuity (Romano et al., 2009;
Lo et al., 2009). Several studies determined the clinical effec-
tiveness of IVB combined with cataract surgery for the man-
agement of the postoperative increase of retinal thickness in
patients with DME. The short-term results suggest that IVB
has the potential not only to prevent the increase in retinal
thickness, but also reduce the retinal thickness of eyes with
DME after cataract surgery (Takamura et al., 2009;
Lanzagorta-Aresti et al., 2009).
3.3. Vitrectomy for persistent diffuse diabetic macular edema
Vitrectomy with removal of the premacular posterior hyaloid
for persistent diffuse macular edema has gained rapid wide-
spread acceptance. The large number of series evaluating the
efﬁcacy of vitrectomy (with or without internal limiting mem-
brane peeling) has yielded conﬂicting results. In a prospective
randomized trial, Stolba et al. (2005) showed that vitrectomy
with internal limiting membrane peeling was superior to obser-
vation in eyes with persistent diffuse diabetic macular edema
that previously failed to respond to conventional laser treatment
and positively inﬂuenced distance and reading visual acuity as
well as the morphology of the edema. However, they suggested
the need for larger follow-up and larger series to conﬁrm these
ﬁndings. Other studies suggested that vitrectomy with and with-
out internal limiting membrane peeling may provide anatomic
and visual beneﬁt in eyes with diffuse nontractional unrespon-
sive DME refractory to laser photocoagulation (Kumagai
et al., 2009; Yamamoto et al., 2007). Best corrected visual acuity
continued to improve until 1 year postoperatively and is main-
tained long term (Kumagai et al., 2009; Yamamoto et al.,
2007). The preoperative best corrected visual acuity was the best
prognostic factor for ﬁnal best corrected visual acuity (Kumagai
et al., 2009; Yamamoto et al., 2007). On the other hand, other
studies showed that the beneﬁts of vitrectomy forDME in terms
of visual acuity and macular thickness were limited to patients
who exhibited signs of macular traction, either clinically and/
or on optical coherence tomography (Shah et al., 2006; Figueroa
et al., 2008). Macular detachment on optical coherence tomog-
raphy was suggested to be an adverse predictive indicator (Shah
et al., 2006). The Diabetic Retinopathy Clinical Research
Network (2010b) evaluated vitrectomy for diabeticmacular ede-
ma associated with vitreomacular traction. At 6 months, med-
ian OCT central subﬁeld thickness decreased by 160 microns,
with 43% having central subﬁeld thickness <250 microns and
68%having at least a 50%reduction in thickening.Visual acuity
improved byP10 letters in 38%and deteriorated byP10 letters
in 22%. The factors associated with favorable outcomes after
vitrectomy for diabetic macular edema were also evaluated
(Flaxel et al., 2010). Greater visual acuity improvement
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an epiretinal membrane was removed. Greater reduction in cen-
tral subﬁeld thickness occurred with worse baseline visual acu-
ity, greater preoperative retinal thickness, removal of internal
limited membrane, and optical coherence tomography evidence
of vitreoretinal abnormalities.
The necessity of internal limiting membrane peeling is still
unclear. Several studies reported that there was no difference
in the absorption rate of macular edema or the functional out-
come after vitrectomy with or without internal limiting mem-
brane peeling (Kumagai et al., 2009; Shiba et al., 2009).
3.4. Pharmacologic vitreolysis in the management of diabetic
retinopathy
Our enhanced understanding of the role of the vitreous body in
diabetic retinopathy has led investigators to use pharmacologic
vitreolysis in the management of diabetic retinopathy. A phase
III clinical trial has shown that 55 IU of highly puriﬁed ovine
hyaluronidase (vitrase) helps to clear vitreous hemorrhage
1 month after intravitreal application (Kuppermann et al.,
2005a,b). No serious safety issues were reported (Kuppermann
et al., 2005a,b). In particular, the incidence of retinal detach-
ment was not statistically different between treated eyes and
control groups.
Quiram et al. (2007) demonstrated that intravitreal injec-
tion of microplasmin with induction of the combination of
posterior vitreous detachment (PVD) and vitreous liquefaction
increased intravitreal oxygen tension. On the other hand, hyal-
uronidase-induced vitreous liquefaction without PVD induc-
tion failed to increase intravitreal oxygen tension. Moreover,
when microplasmin treated animals were exposed to 100%
oxygen, there was an accelerated increase in oxygen levels in
the midvitreous cavity compared to control or hyaluronidase
treated eyes. These ﬁndings suggest that the beneﬁcial effects
of surgical vitrectomy in increasing oxygen tension in the vitre-
ous cavity (Stefa´nsson, 2009) may be reproduced with enzy-
matic induction of PVD and vitreous liquefaction without
the time, risks, and expense of surgery.
It is more difﬁcult to separate the vitreous cortex from the
internal limiting membrane in diabetic eyes than in nondia-
betic eyes. This is likely due to the effects of diabetes on the
macromolecules of vitreous and the structural consequences
(Zhi-Liang et al., 2009). In an experimental rat model of diabe-
tes, the combination of hyaluronidase causing vitreous lique-
faction and plasmin acting as a PVD inducer was more
effective than plasmin alone in inducing complete PVD (Zhi-
Liang et al., 2009).
Pilot clinical studies in diabetic eyes found that autologous
plasmin was a safe and effective adjunct to vitrectomy for
DME and PDR. Intravitreal injection of autologous plasmin
enzyme before surgery was useful in inducing a pharmacologic
PVD, and thus mechanical PVD was not necessary in the eyes
with DME secondary to posterior vitreous cortex contraction
(Sakuma et al., 2006; Azzolini et al., 2004; Asami et al., 2004).
Plasmin-assisted vitrectomy allowed a more complete and less
traumatic posterior vitreous cortex removal with a smooth ret-
inal surface. The internal limiting membrane removed during
the plasmin-assisted vitrectomy from eyes with diabetic macu-
lar edema demonstrated cleaner and ﬂatter surfaces, whereas
the internal limiting membrane removed without the use of
autologous plasmin enzyme had remnants of the vitreouscortex more frequently (Asami et al., 2004). Autologous plas-
min enzyme was also beneﬁcial in the surgical management of
PDR. The proliferative membranes became softened and were
easily peeled without retinal tears (Hirata et al., 2007).
Recently, Diaz-Llopis et al. (2009) demonstrated that intra-
vitreal injection of autologous plasmin enzyme without the
performance of vitrectomy induced complete PVD and effec-
tively reduced macular thickening due to refractory diffuse dia-
betic macular edema and improved visual acuity. Therefore,
atraumatic pharmacologic separation of the posterior vitreous
cortex with clean cleavage between the internal limiting mem-
brane and the posterior hyaloids without performing a vitrec-
tomy can reduce the risk of intraoperative iatrogenic damage
such as retinal tears, and damage to the nerve ﬁbers, and the
postoperative sequelae.
3.5. Fibrates
Fibrates are widely prescribed lipid-lowering drugs in the treat-
ment of dyslipidemia. Their main clinical effects, mediated by
peroxisome proliferative activated receptor alpha activation,
are a moderate reduction in total cholesterol and low-density
lipoprotein cholesterol levels, a marked reduction in triglycer-
ides and an increase in high-density lipoprotein cholesterol.
The Fenoﬁbrate Intervention and Event Lowering in Diabetes
(FIELD) Study demonstrated that long-term lipid-lowering
therapy with fenoﬁbrate reduced the progression of diabetic
retinopathy and the need for laser treatment in patients with
type 2 diabetes, although the mechanism of this effect does
not seem to be related to plasma concentration of lipids (Keech
et al., 2007). Recently, ACCORD Study Group (2010) demon-
strated that fenoﬁbrate for intensive dyslipidemia therapy re-
duced the rate of progression of diabetic retinopathy in
persons with type 2 diabetes (ACCORD Study Group, 2010).
3.6. Renin-angiotensin system (RAS) blockers
Several studies suggested that RAS blockers might reduce the
burden of diabetic retinopathy. The ﬁndings of the Eurodiab
Controlled trial of Lisinopril in Insulin-dependent Diabetes
(EUCLID) suggested that blockade of the renin-angiotensin
system with the angiotensin-converting enzyme inhibitor lisin-
opril could reduce both incidence and progression of retinop-
athy in type 1 diabetes (Chaturvedi et al., 1998). Recently,
the Diabetic Retinopathy Candesartan Trials (DIRECT) dem-
onstrated that the angiotensin-receptor antagonist candesartan
reduced the incidence of retinopathy in patients with type 1
diabetes (Chaturvedi et al., 2008), and might induce improve-
ment of retinopathy in type 2 diabetic patients with mild-to-
moderate retinopathy (Sjølie et al., 2008).
3.7. Peroxisome proliferator-activated receptor gamma (PPAR-
c) agonists
The PPARc agonist rosiglitazone inhibited both the retinal
leukostasis and retinal leakage observed in the experimental
diabetic rats. In addition, the decreased expression of the
endogenous PPARc in mice leads to the aggravation of retinal
leukostasis and retinal leakage in diabetic mice (Muranaka
et al., 2006). Rosiglitazone maleate (Avandia; GlaxoSmithK-
line, North Carolina, USA) is an orally administered
medication used to improve glycemic control in patients with
Advances in the treatment of diabetic retinopathy 119diabetes mellitus. This medication activates the PPARc and
leads to insulin sensitization in adipose and other tissues, with
potential antiangiogenic activity. Recently, Shen et al. (2008)
demonstrated that rosiglitazone may delay the onset of PDR
in patients with severe nonproliferative diabetic retinopathy
at the baseline. Several studies showed that the use of glitazone
class of drugs was associated with DME (Fong and Contreras,
2009). However, another retrospective study concluded that
rosiglitazone is not linked to DME (Tatti et al., 2008).
3.8. Ruboxistaurin
Hyperglycemia activates protein kinase C (PKC) by inducing de
novo synthesis of diacylglycerol, a physiologic activator of
PKC. Substantial data suggest that the b isoform may play an
important role in the development of diabetic microvascular
complications. Increased PKC b isoform activity induces retinal
vascular permeability and neovascularization in animal models.
Roboxistaurin (RBX) (LY333531; Lilly Research Laboratories,
Indianapolis, Indiana, USA) is a PKC b-selective inhibitor with
adequate bioavailability to permit oral administration once dai-
ly. In the Protein Kinase C b inhibitor-Diabetic Retinopathy
Study 2 (PKC-DRS2), oral administration of RBX (32 mg per
day) reduced sustainedmoderate visual loss, need for laser treat-
ment formacular edema, andmacular edema progression, while
increasing occurrence of visual improvement in patients with
nonproliferative retinopathy (PKC-DRS2 Group, 2006). In
the ProteinKinaseC b inhibitorDiabeticMacular Edema Study
(PKC-DMES), RBX treatment also showed a beneﬁcial effect
on DME progression relative to placebo (PKC-DMES Study
Group, 2007). More recently, Davis et al. (2009) demonstrated
that RBX treatment appears to ameliorate DME-associated vi-
sual decline.
3.9. Islet cell transplantation
Recent studies demonstrated that improved islet transplant
outcomes could be observed with enhanced islet isolation, glu-
cocorticoid-free immunosuppression, and provision of an ade-
quate islet mass of more than 10,000 islet equivalents per kg of
body weight. These improvements have resulted in beneﬁts to
type 1 diabetic subjects, including long-term c-peptide secre-
tion, improved glycemic control, and reduced hypoglycemic
episodes. Recently, it was demonstrated that islet transplanta-
tion yields improved HbA1c and less progression of retinopa-
thy compared with intensive medical therapy during 3 years of
follow-up (Warnock et al., 2008; Thompson et al., 2008).Acknowledgments
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